Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) has shared an announcement.
Extrawell Pharmaceutical Holdings Limited has granted a total of 76.5 million share options, representing about 3% of its issued share capital, to three executive directors under its 2022 share option scheme. The options, granted on 19 December 2025 at an exercise price of HK$0.0936 per share, will vest 12 months after the grant date and can be exercised for up to 10 years thereafter, with a nominal acceptance consideration and no performance targets attached, but subject to a clawback mechanism tied to misconduct and employment termination. The move underscores the company’s use of equity-based incentives to align management interests with shareholders, while limiting dilution through a relatively small percentage of new shares and confirming no financial assistance was provided to grantees for exercising the options.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is a Bermuda-incorporated company listed in Hong Kong and engaged in the pharmaceutical sector through its subsidiaries. The Group focuses on the development, manufacture and sale of pharmaceutical products, serving the healthcare market primarily through its operations in Greater China.
Average Trading Volume: 2,642,950
Technical Sentiment Signal: Hold
Current Market Cap: HK$237.2M
See more insights into 0858 stock on TipRanks’ Stock Analysis page.